Immune-Checkpoint-Inhibitor-Induced Severe Autoimmune Encephalitis Treated by Steroid and Intravenous Immunoglobulin

참고문헌 (13)

1. Krishnamurthy A, "Atezolizumab: a novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers", Drugs Today(Barc), 53, pp.217~237 (2017)
2. Fellner A, "Neurologic complications of immune checkpoint inhibitors", J Neurooncol, 137, pp.601~609 (2018)
3. "TECENTRIQ® (atezolizumab) injection, for intravenous use" (2018)[URL]
4. Blackmon JT, "Central nervous system toxicities of anti-cancer immune checkpoint blockade", J Neurol Neuromed, 1, pp.39~45 (2016)
5. Ito M, "Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient", Ann Oncol, 28, pp.2318~2319 (2017)
6. Williams TJ, "Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer", JAMA Neurol, 73, pp.928~933 (2016)
7. Maurice C, "Subacute CNS demyelination after treatment with nivolumab for melanoma", Cancer Immunol Res, 3, pp.1299~1302 (2015)
8. Hottinger AF, "Natalizumab may control immune checkpoint inhibitorinduced limbic encephalitis", Neurol Neuroimmunol Neuroinflamm, 5, pp.e439~ (2018)
9. Levine JJ, "Atezolizumab-induced encephalitis in metastatic bladder cancer : a case report and review of the literature", Clin Genitourin Cancer, 15, pp.e847~e849 (2017)[DOI]
10. Laserna A, "Atezolizumab-related encephalitis in the intensive care unit : case report and review of the literature", SAGE Open Med Case Rep, 6 (2018)[DOI]
11. Sacco E, "Paraneoplastic syndromes in patients with urological malignancies", Urol Int, 83, pp.1~11 (2009)
12. Darnell RB, "Paraneoplastic syndromes involving the nervous system", N Engl J Med, 349, pp.1543~1554 (2003)
13. Stroh M, "Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma", Clin Pharmacol Ther, 102, pp.305~312 (2017)

관련 논문AI추천